KYORIN Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yutaka Ogihara
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7yrs |
| CEO ownership | 14.1% |
| Management average tenure | 2.8yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO
Yutaka Ogihara (59 yo)
Mr. Yutaka Ogihara has been Representative Director and President of KYORIN Pharmaceutical Co., Ltd. since June 2019 and serves as its Chief Executive Officer since April 2023. He serves as Chairman of KYO...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7yrs | no data | 14.05% $ 57.6m | |
| CFO, CSO | 3.2yrs | no data | 0.0047% $ 19.2k | |
| Managing Executive Officer | no data | no data | no data | |
| Managing Executive Officer | 2.4yrs | no data | no data | |
| Senior Managing Executive Officer & Chief Business Development Officer | no data | no data | no data | |
| Managing Exe. Officer | no data | no data | no data | |
| Corporate Officer & President of KYORIN Pharmaceutical Group Facilities Co. | 1.4yrs | no data | no data |
Experienced Management: KYRN.F's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 15yrs | no data | 14.05% $ 57.6m | |
| CFO, CSO | 2yrs | no data | 0.0047% $ 19.2k | |
| Managing Exe. Officer | no data | no data | no data | |
| Chairman of Corporate Auditors | 8yrs | no data | 0.037% $ 152.7k | |
| Independent Outside Director | no data | no data | no data | |
| Full-time Audit & Supervisory Board Member | 4yrs | no data | 0.024% $ 97.4k | |
| Outside Audit & Supervisory Board Member | 11yrs | no data | 0.0050% $ 20.7k | |
| Independent Outside Director | 9yrs | no data | 0.0092% $ 37.8k | |
| Independent Outside Director | 7yrs | no data | 0.0052% $ 21.4k | |
| Outside Audit & Supervisory Board Member | 4yrs | no data | 0.0016% $ 6.4k | |
| Outside Audit & Supervisory Board Member | 4yrs | no data | 0.0016% $ 6.4k | |
| Audit & Supervisory Board Member | no data | no data | no data |
Experienced Board: KYRN.F's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 01:08 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KYORIN Pharmaceutical Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |